ADC Therapeutics Ltd (ADCT) just unveiled an update.
ADC Therapeutics SA is hosting a virtual investor event to showcase their latest breakthroughs in cancer treatment with a focus on their innovative exatecan-based antibody drug conjugate platform. The event, led by CEO Ameet Mallik and Chief Scientific Officer Patrick van Berkel, PhD, will include a comprehensive presentation followed by a live Q&A session, offering insight into the company’s research advancements and future prospects in the pharmaceutical industry.
See more insights into ADCT stock on TipRanks’ Stock Analysis page.
